Professor and Chief, Division of Surgical Oncology
University of Rochester
Rochester, New York, United States
I am a Professor, Vice-Chair of Basic and Translational Research, and Division Chief of Surgical Oncology, in the Department of Surgery at the University of Rochester School of Medicine and Dentistry. For the Wilmot Cancer Institute, I serve as co-Leader of the Genetics, Epigenetics and Metabolism Research Program. My clinical area of expertise is in the managment of patients with Hepatobiliary and Pancreatic Cancers. I served as co-leader of the Hepatobiliary and Gastrointestinal Clinical Cancer Programs in my former position at Rutgers Cancer Institute of New Jersey and I am the national PI of a multi-center phase II trial testing a novel cancer vaccine in combination with Nivolumab in patients with resectable metastatic colorectal cancer. I am the PI of a basic/translational cancer research lab that focuses on developmental therapeutics in cancer dormancy. We are currently developing a novel class of anti-cancer drugs that target mutant p53 that have lead to 8 patents and a biotech startup. Our research is funded by numerous grants from the NIH, and foundations such as the Pancreatic Cancer Action Network, Sidney Kimmal Cancer Foundation, Harrington Foundation and the Breast Cancer Research Foundation. I serve as a regular member for the NIH's Drug Discovery and Molecular Pharmacology study section as well as numerous ad hoc study section including the NCI K08 and Pancreatic Cancer Action Network. I also serve on numerous editorial boards of cancer research journals.
Z53 Therapeutics, Inc. (Individual(s) Involved: Self): Ownership Interest
Wednesday, March 9, 2022
2:11 PM – 2:21 PM CST
Friday, March 11, 2022
10:00 AM – 11:30 AM CST